Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs Vertiv Holdings Co (VRT) Price & Performance

IDEXX Laboratories, Inc.Trade
Vertiv Holdings CoTrade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs Vertiv Holdings Co — how do they compare? IDEXX Laboratories, Inc. trades at $586.65 (market cap $46.93B), while Vertiv Holdings Co trades at $285.9 (market cap $103.99B). The key difference: Vertiv Holdings Co is far larger — about 2.2× IDEXX Laboratories, Inc.'s market cap, and Vertiv Holdings Co pays a 0.09% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

IDXXVRT
Market Cap
$46.93B$103.99B
Sector
HealthTechnology
52-Week High
$766.68$376.23
52-Week Low
$526.44$121.82
Enterprise Value
$47.83B$104.21B
Dividend Yield
0.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories trades at $586.67, down 0.56% on the day, with strong technical momentum showing bullish moving averages and key resistance at $590. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.27 beating estimates by 8.4% and full-year guidance raised to $14.69-14.94. Revenue growth accelerated to 10% year-over-year, supported by 9% organic growth in companion animal diagnostics. Net income margin expanded to 25.03% with exceptional ROE of 74.21%, though valuation multiples remain elevated at P/E 41.23.

Outlook remains positive with analyst consensus at 56.5% buy ratings, though premium valuation and competitive pressures present risks. The stock's technical setup suggests potential breakout above $590 resistance could target $609-618 levels, while support at $578-570 provides downside protection. Continued execution on international expansion and diagnostic adoption supports growth trajectory.

Vertiv Holdings Co

VRT trades at $272.40, down 1.01% on the day, with a bearish technical signal driven by moving averages and RSI levels near overbought territory. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.52 versus $1.43 expected, and revenue growth is supported by AI data center demand. Recent news highlights its role in AI infrastructure, though legal investigations pose a sentiment risk.

Outlook remains positive with a consensus price target of $386.58, reflecting 42% upside, driven by robust fundamentals and AI tailwinds. Risks include high valuation multiples, competitive pressures, and ongoing legal scrutiny. Investors should weigh growth potential against elevated P/E and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX

About Vertiv Holdings Co

Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.

Read more on VRT